$TORNTPHARM

Fundamental: Revenue +41.9% YoY | 5Y PAT CAGR 28.8% | P/E 70.6x vs sector 40.9x (premium to peers) | Upside 16.3% | Operating Margin 31.8% | ROCE 13.9% | Rank #5/14 peers | Rating 7.81 Technical: Broke above ₹4,500 resistance — now trading near recent highs | Above all key moving averages — uptrend well-established | HH-HL structure intact | RSI 63 healthy momentum | ADX 20 — trend gaining strength Moat: India's fourth-largest branded generics player with a dominant chronic therapy franchise (cardiology, CNS, GI) and a fast-growing Germany business — brand depth and chronic mix create sticky, recurring revenue that is difficult to dislodge. View: A proven long-term compounder re-rating on revenue momentum — valuation is at a premium, but the brand franchise, chronic therapy dominance, and improving international mix justify it for quality-focused investors.